# Hervé Avet‐Loiseau

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/herve-avet-loiseau/

## Facts

| Field | Value |
| --- | --- |
| Citations | 55,522 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 114 |
| i10-index | 381 |
| Last Known Institution | Centre Hospitalier Universitaire de Toulouse |
| OpenAlex ID | https://openalex.org/A5063422967 |
| ORCID iD | https://orcid.org/0000-0002-3050-0140 |
| Works | 1,089 |

## Researcher papers

- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-with-transplantation-for-myeloma/)
- [Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study](https://scholariq.org/papers/bortezomib-thalidomide-and-dexamethasone-with-or-without-daratumumab-before-and/)
- [Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma](https://scholariq.org/papers/lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-myeloma/)
- [Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma](https://scholariq.org/papers/triplet-therapy-transplantation-and-maintenance-until-progression-in-myeloma/)
- [Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu](https://scholariq.org/papers/anti-cs1-humanized-monoclonal-antibody-huluc63-inhibits-myeloma-cell-adhesion/)
- [Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma](https://scholariq.org/papers/biallelic-loss-of-bcma-as-a-resistance-mechanism-to-car-t-cell-therapy-in-a/)
- [Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial](https://scholariq.org/papers/maintenance-with-daratumumab-or-observation-following-treatment-with-bortezomib/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)

## Researcher university

- [Centre Hospitalier Universitaire de Toulouse](https://scholariq.org/institutions/centre-hospitalier-universitaire-de-toulouse/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.